Description
Release form
Intravenous solution 20 mg / ml.
Packaging
5 ml, 10 ml of the preparation in neutral glass ampoules with a notch marked with a dot (paint). 10 ampoules are placed in a blister strip packaging from a film of polyvinyl chloride. 1 blister strip packaging along with instructions for use, a scarifier or ampoule knife is placed in a cardboard box.
Pharmacological action
Pharmacotherapeutic group:
metabolic agent.
KODATH: [C01EV].
Pharmacological properties:
Riboxin – a derivative (nucleoside) of purine – a precursor of ATP adenosine diphosphate. Refers to a group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the effects of intraoperative renal ischemia. It is directly involved in the metabolism of glucose and contributes to the activation of metabolism in conditions of hypoxia and in the absence of ATP.
Activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides, enhances the activity of some enzymes of the Krebs cycle. Penetrating into the cells, it has a positive effect on metabolic processes in the myocardium – it increases the force of contractions of the heart and contributes to a more complete relaxation of the myocardium in the diastole, as a result of which the stroke volume increases. The mechanism of antiarrhythmic action is not completely clear.
Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).
Pharmacokinetics
Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.
Indications
Comprehensive treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against the background of myocardial dystrophy after infections.
Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).
Surgery on an isolated kidney (as a means of pharmacological protection when turning off blood circulation).
Contraindications
Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety have not been established).
Use with caution in renal failure.
Composition of
1 ml of solution contains:
active substance:
inosine (riboxin) 20 mg,
excipients:
propylene glycol,
sodium hydroxide,
sodium sulfite anhydrous,
water for injection.
Description:
Colorless or slightly colored clear liquid.
Dosage and administration
The drug is administered intravenously, slowly or dropwise (40-60 drops per minute). Treatment begins with the introduction of 200 mg (10 ml of a 2% solution) once a day, then, with good tolerance, the dose is increased to 400 mg (20 ml of a 2% solution) 1-2 times a day.
Duration of treatment is 10-15 days.
Inkjet administration of the drug is possible with acute cardiac arrhythmias in a single dose of 200-400 mg.
For the pharmacological protection of ischemic kidneys, riboxin is administered intravenously in a single dose of 1.2 g (60 ml of a 2% solution) 5-15 minutes before compressing the renal artery, and then another 0.8 g (40 ml of 2% solution) immediately after restoration of blood circulation.
When dropping into a vein, a 2% solution of the drug is diluted in a 5% solution of dextrose (glucose) or isotonic sodium chloride solution (up to 250 ml).
Side effects
Allergic reactions: pruritus, hyperemia of the skin (the drug should be discontinued).
Rarely: increased concentration of uric acid in the blood, exacerbation of gout (with prolonged use).
Storage conditions
In a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
Shelf life
3 years.
Do not use after expiration date.
active substance
Inosine
Terms of sale from
pharmacies Prescription
